EUVIMEDEUVIMED entdecken
Fallbericht

Haploidentical Hematopoietic Cell Transplantation With Post‐Transplant Cyclophosphamide for Pediatric Chronic Active Epstein–Barr Virus Infection

Kentaro Fujimori iD, Kenichi Sakamoto iD, Shinichi Tsujimoto, Masaki Yamada iD, Yoshihiro Gocho, Takao Deguchi, Akihiro Iguchi, Hirotoshi Sakaguchi iD, Motohiro Kato iD, Ken-Ichi Imadome, Kimikazu Matsumoto, Daisuke Tomizawa und 1 weitere

Pediatric Transplantation · 2025

DOI: 10.1111/petr.70165 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Kentaro Fujimori und 12 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Infections, Cyclophosphamide, Immunosuppressive Agents. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Ministry of Health, Labour and Welfare, National Center for Child Health and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hematopoietic cell transplantation (HCT) is the only curative treatment for chronic active Epstein–Barr virus infection (CAEBV). While HCT is needed at the appropriate time, there are sometimes difficulties in securing an appropriate donor, making HLA haploidentical donor an alternative option. Recently, post‐transplant cyclophosphamide (PTCy) has rapidly gained popularity as a safe graft‐versus‐host disease (GVHD) prevention strategy for HCT from HLA haploidentical donors; however, there are only a few reports of its use for CAEBV.

Method

A retrospective chart review was completed for two pediatric CAEBV cases who underwent HLA haploidentical HCT (Haplo‐HCT) with PTCy.

Result

A 6‐year‐old girl diagnosed with CAEBV previously underwent HCT twice from an HLA 8/8 matched brother, which both failed due to secondary graft failure. A third HCT was planned with a peripheral blood stem cell from her haploidentical father. She received a busulfan‐based reduced intensity conditioning regimen. PTCy, mycophenolate mofetil, and tacrolimus were used for GVHD prophylaxis. Engraftment was achieved with full donor chimerism, and she remained in complete remission. A 7‐year‐old girl also diagnosed with CAEBV underwent HCT from her haploidentical mother with the same conditioning regimen and GVHD prophylaxis as the previous case. Engraftment was achieved with full donor chimerism. She suffered grade II (skin stage 3) acute GVHD and transplant‐associated thrombotic microangiopathy, which were both treated successfully. She remained in complete remission.

Conclusions

Haplo‐HCT with PTCy was safely performed for two pediatric CAEBV patients. Haplo‐HCT may be a useful transplant option for CAEBV patients without a matched donor option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationEpstein-Barr Virus InfectionsCyclophosphamideImmunosuppressive AgentsTransplantation, HaploidenticalHumansChildFemaleGraft vs Host DiseaseRetrospective StudiesTransplantation ConditioningChronic DiseaseMale

Stichwörter der Autor:innen

chronic active Epstein–Barr virus infectionhaploidentical stem cell transplantationpediatricpost‐transplantation cyclophosphamide

Substanzen

CyclophosphamideImmunosuppressive Agents

Autor:innen und Institutionen

  • Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Advanced Medicine for Virus Infections, National Center for Child Health and Development, Tokyo, Japan.

ORCID-Profile: Kentaro Fujimori, Kenichi Sakamoto, Masaki Yamada, Hirotoshi Sakaguchi, Motohiro Kato

Förderung

  • Ministry of Health, Labour and Welfare
  • National Center for Child Health and Development

Zitieren

APA

Fujimori, K., Sakamoto, K., Tsujimoto, S., Yamada, M., Gocho, Y., Deguchi, T., Iguchi, A., Sakaguchi, H., Kato, M., Imadome, K. I., Matsumoto, K., Tomizawa, D., & Osumi, T. (2025). Haploidentical Hematopoietic Cell Transplantation With Post‐Transplant Cyclophosphamide for Pediatric Chronic Active Epstein–Barr Virus Infection. Pediatric Transplantation. https://doi.org/10.1111/petr.70165

Vancouver

Fujimori K, Sakamoto K, Tsujimoto S, Yamada M, Gocho Y, Deguchi T, et al. Haploidentical Hematopoietic Cell Transplantation With Post‐Transplant Cyclophosphamide for Pediatric Chronic Active Epstein–Barr Virus Infection. Pediatric Transplantation. 2025. doi:10.1111/petr.70165

BibTeX
@article{Fujimori2025,
  author = {Fujimori, Kentaro and Sakamoto, Kenichi and Tsujimoto, Shinichi and Yamada, Masaki and Gocho, Yoshihiro and Deguchi, Takao and Iguchi, Akihiro and Sakaguchi, Hirotoshi and Kato, Motohiro and Imadome, Ken-Ichi and Matsumoto, Kimikazu and Tomizawa, Daisuke and Osumi, Tomoo},
  title = {Haploidentical Hematopoietic Cell Transplantation With Post‐Transplant Cyclophosphamide for Pediatric Chronic Active Epstein–Barr Virus Infection},
  journal = {Pediatric Transplantation},
  year = {2025},
  doi = {10.1111/petr.70165}
}
Kostenlos starten →